JAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 47/36

A1

(11) International Publication Number: WO 93/16733

(43) International Publication Date: 2 September 1993 (02.09.93)

(21) International Application Number: PCT/CA93/00062

(22) International Filing Date: 16 February 1993 (16.02.93)

(30) Priority data:
2,061,566 20 February 1992 (20.02.92) CA

(71) Applicant *(for all designated States except US)*: NORPHARMCO INC. [CA/CA]; 890 Yonge Street, Second Floor, Toronto, Ontario M4W 3P4 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)* : FALK, Rudolf, Edgar [CA/CA]; 40 Riverview Drive, Toronto, Ontario M4N 3C7 (CA). ASCULAI, Samuel, Simon [US/CA]; 53 McCaul Street, Apartment #TH13, Toronto, Ontario M6M 2B6 (CA).

(74) Agents: HUGHES, Ivor, M. et al.; 175 Commerce Valley Drive, Suite 200, Thornhill, Ontario L3T 7P6 (CA).

(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published
With international search report.

(54) Title: TOPICAL COMPOSITION CONTAINING HYALURONIC ACID AND NSAIDS

(57) Abstract

A pharmaceutical composition comprising a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment suffering from a disease or condition, each such dosage amount comprising a therapeutically effective non-toxic (to the patient) dosage amount of a drug for the treatment of the disease and/or condition of the skin and/or exposed tissue at the site of the pathology and/or trauma and an effective non-toxic dosage amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid to transport (to facilitate or cause the transport of) the drug to the site of the pathology and/or trauma of the disease or condition.